Nitrosamine impurities are trace amounts of cancer-causing chemicals that can form unintentionally in medications during manufacturing. They belong to a class of compounds built around a deceptively simple chemical structure: two nitrogen atoms bonded together with an oxygen atom attached (the N-N=O group). These impurities gained widespread attention starting in 2018 when they were discovered in common blood pressure and heartburn medications, triggering major recalls and a global regulatory response that continues today.
How Nitrosamines Form
Nitrosamines form when nitrogen-containing compounds called amines react with nitrosating agents, which are chemicals capable of donating a “nitroso” group. In pharmaceutical manufacturing, this reaction can happen in surprisingly mundane ways. Sodium nitrite, a known impurity in some starting materials like sodium azide, can react with amines under acidic conditions to produce nitrosamines. Even fresh solvents like toluene and methylene chloride have been found to contain nitrosamines carried over during transfer between storage vessels.
Recovered solvents pose a particular risk. Drug manufacturers routinely recycle solvents to reduce costs, but if a recovery process involves a quenching step using nitrous acid, nitrosamines can form and persist in the recycled material. When a manufacturing site produces the same drug using multiple processes that share common solvents, the solvents sent for recovery can become contaminated. The problem gets worse when solvent recovery is outsourced to third-party contractors who may not receive detailed information about what the materials contain.
Cross-contamination at manufacturing sites adds another layer of risk. If a facility produces multiple drugs on shared equipment, nitrosamine impurities from one process can carry over into another. Raw materials, intermediates, and even the equipment itself can serve as vehicles for contamination.
Why They’re Dangerous
Nitrosamines are classified as probable or possible human carcinogens. Over 300 structurally different nitrosamines are known, and more than 20 have been formally assessed for cancer risk by the International Agency for Research on Cancer. The concern isn’t about a single large exposure. It’s about the cumulative effect of ingesting tiny amounts daily over months or years, particularly in medications people take for chronic conditions.
The way nitrosamines damage the body is well understood. They are “pro-carcinogens,” meaning they aren’t directly harmful in their original form. Instead, liver enzymes convert them into reactive molecules called alkylating agents. These molecules chemically bond to DNA, creating abnormal structures called adducts at multiple points along the genetic code. These adducts can interfere with DNA replication and repair, potentially triggering the mutations that lead to cancer. The alkylation can occur at both the oxygen and nitrogen atoms within DNA’s building blocks, as well as along the DNA backbone itself, making the damage widespread rather than targeted.
Medications Affected by Recalls
The first major discovery came in 2018, when NDMA (the most common nitrosamine impurity) was found in valsartan, a widely prescribed blood pressure medication in the sartan drug class. Testing soon revealed contamination in other sartan drugs as well, leading to recalls across multiple manufacturers.
The highest-profile case involved ranitidine, sold under the brand name Zantac. In April 2020, the FDA requested that all prescription and over-the-counter ranitidine products be removed from the market. Unlike other contaminated drugs where nitrosamines were introduced during manufacturing, ranitidine had a unique problem: the NDMA levels in the drug increased over time and at higher storage temperatures, meaning the medication could become increasingly contaminated just sitting on a shelf or in a medicine cabinet. The FDA confirmed that other heartburn medications, including famotidine (Pepcid), cimetidine (Tagamet), esomeprazole (Nexium), lansoprazole (Prevacid), and omeprazole (Prilosec), did not contain NDMA.
Metformin, the most commonly prescribed diabetes medication worldwide, was also flagged for nitrosamine contamination, leading to recalls of certain extended-release formulations. The pattern across these cases is consistent: drugs taken daily for years, where even nanogram-level contamination becomes meaningful over time.
How Much Is Considered Safe
Regulators set acceptable daily intake limits measured in nanograms, which are billionths of a gram. For NDMA, the most frequently detected nitrosamine impurity, the FDA’s limit is 96 nanograms per day. For NDEA, another common variant, the limit is even lower at 26.5 nanograms per day. These thresholds are calculated to represent a cancer risk of approximately 1 in 100,000 over a lifetime of daily exposure.
To put that in perspective, 96 nanograms is roughly equivalent to the weight of a single grain of sand divided into tens of thousands of pieces. Detecting contamination at these levels requires extremely sensitive laboratory equipment. The standard method uses a technique called liquid chromatography paired with tandem mass spectrometry, which can identify and measure nitrosamines down to 0.01 parts per million in drug substances. This sensitivity is essential because the safety limits are so extraordinarily low.
How Manufacturers Prevent Contamination
Prevention starts with understanding the chemistry. Since nitrosamines form most readily under acidic conditions, one approach involves modifying a drug’s formulation to create a neutral or basic environment inside the pill or capsule. Adding excipients like sodium carbonate shifts the internal pH away from the acidic range where nitrosamine-forming reactions accelerate.
Antioxidants offer another line of defense. Research originally showed that vitamin C (ascorbic acid) and vitamin E (alpha-tocopherol) could block nitrosamine formation in the stomach. Pharmaceutical scientists have adapted this concept, incorporating these antioxidants directly into drug formulations. Preliminary work suggests this approach can significantly reduce the formation of nitrosamine impurities within the finished product.
On the supply chain side, the FDA now expects manufacturers to run supplier qualification programs that account for potential nitrite contamination across different excipient suppliers and individual lots of raw materials. This means tracking not just what goes into a drug, but what impurities might be lurking in each ingredient from each supplier. Manufacturers also need to carefully evaluate their solvent recovery processes, avoid commingling solvents from different production lines, and ensure that third-party recovery facilities have enough information to handle materials safely.
What This Means for People Taking Medications
The discovery of nitrosamine impurities reshaped how the pharmaceutical industry thinks about drug safety. Before 2018, most manufacturers were not routinely testing for these compounds. Now, the FDA requires all drug makers to evaluate their products for nitrosamine risk and test when that risk exists.
If you take a medication that was previously recalled for nitrosamine contamination, reformulated versions with lower or undetectable levels are typically what’s now on the market. The risk from short-term exposure to contaminated medications is extremely small. The concern has always been about cumulative exposure over years, which is why the regulatory response focused on long-term daily medications rather than drugs taken occasionally. Storing medications according to label instructions, particularly keeping them away from heat, also helps minimize any potential for nitrosamine levels to increase over time in the product.